Denise Lepley

780 total citations
18 papers, 650 citations indexed

About

Denise Lepley is a scholar working on Molecular Biology, Oncology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Denise Lepley has authored 18 papers receiving a total of 650 indexed citations (citations by other indexed papers that have themselves been cited), including 9 papers in Molecular Biology, 7 papers in Oncology and 5 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Denise Lepley's work include Ovarian cancer diagnosis and treatment (4 papers), Renal cell carcinoma treatment (3 papers) and Cancer Genomics and Diagnostics (3 papers). Denise Lepley is often cited by papers focused on Ovarian cancer diagnosis and treatment (4 papers), Renal cell carcinoma treatment (3 papers) and Cancer Genomics and Diagnostics (3 papers). Denise Lepley collaborates with scholars based in United States, Spain and Italy. Denise Lepley's co-authors include Jill C. Pelling, Diane F. Birt, Boyong Li, Timothy Hla, Fernando Ferrer, Jihye Paik, Kathy A. Suprenant, Jenny Devenport, Natasha Singh and Joel Kremer and has published in prestigious journals such as Journal of Biological Chemistry, Journal of Clinical Oncology and Cancer Research.

In The Last Decade

Denise Lepley

16 papers receiving 629 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Denise Lepley United States 8 412 119 109 98 79 18 650
Fen-Fen Lin United States 14 644 1.6× 202 1.7× 71 0.7× 63 0.6× 65 0.8× 17 1.0k
Linette Castillo‐Pichardo Puerto Rico 10 467 1.1× 131 1.1× 139 1.3× 47 0.5× 92 1.2× 19 753
Yancun Yin China 18 654 1.6× 198 1.7× 186 1.7× 79 0.8× 63 0.8× 33 1.2k
Zachary R. Healy United States 9 328 0.8× 54 0.5× 74 0.7× 61 0.6× 31 0.4× 17 567
Chang-Hyun Yun South Korea 6 323 0.8× 119 1.0× 44 0.4× 39 0.4× 45 0.6× 6 638
Hideharu Odai Japan 13 529 1.3× 134 1.1× 138 1.3× 43 0.4× 45 0.6× 21 858
Li‐Xing Feng China 16 579 1.4× 90 0.8× 84 0.8× 148 1.5× 10 0.1× 30 854
Hsin‐Jung Wu United States 10 343 0.8× 83 0.7× 63 0.6× 30 0.3× 25 0.3× 16 685
Junn-Liang Chang Taiwan 18 492 1.2× 249 2.1× 112 1.0× 38 0.4× 21 0.3× 28 856

Countries citing papers authored by Denise Lepley

Since Specialization
Citations

This map shows the geographic impact of Denise Lepley's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Denise Lepley with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Denise Lepley more than expected).

Fields of papers citing papers by Denise Lepley

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Denise Lepley. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Denise Lepley. The network helps show where Denise Lepley may publish in the future.

Co-authorship network of co-authors of Denise Lepley

This figure shows the co-authorship network connecting the top 25 collaborators of Denise Lepley. A scholar is included among the top collaborators of Denise Lepley based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Denise Lepley. Denise Lepley is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

18 of 18 papers shown
1.
Chan, Nancy, Virginia Kaklamani, Sara M. Tolaney, et al.. (2025). Elacestrant combinations in patients (pts) with ER+/HER2- locally advanced or metastatic breast cancer (mBC): Safety update from ELEVATE, a phase (Ph) 1b/2, open-label, umbrella study.. Journal of Clinical Oncology. 43(16_suppl). 1079–1079.
2.
3.
Liao, Mingxiang, Jie Zhou, Kenton Wride, et al.. (2022). Population Pharmacokinetic Modeling of Lucitanib in Patients with Advanced Cancer. European Journal of Drug Metabolism and Pharmacokinetics. 47(5). 711–723. 4 indexed citations
4.
Oaknin, Ana, Floor Backes, Els Van Nieuwenhuysen, et al.. (2022). LIO-1: Initial phase 2 experience of lucitanib + nivolumab in patients with metastatic or recurrent cervical cancer (NCT04042116; ENGOT-GYN3/AGO/LIO) (034). Gynecologic Oncology. 166. S24–S24. 4 indexed citations
5.
Patel, Manish R., Vicky Makker, Ana Oaknin, et al.. (2022). Efficacy and safety of lucitanib + nivolumab in patients with advanced gynecologic malignancies: Phase 2 results from the LIO-1 study (NCT04042116; ENGOT-GYN3/AGO/LIO).. Journal of Clinical Oncology. 40(16_suppl). 5517–5517. 2 indexed citations
6.
Dumbrava, Ecaterina E., Geoffrey I. Shapiro, Johanna C. Bendell, et al.. (2021). Phase 1b/2 SEASTAR trial: Safety, pharmacokinetics, and preliminary efficacy of the poly(ADP)-ribose polymerase (PARP) inhibitor rucaparib and angiogenesis inhibitor lucitanib in patients with advanced solid tumors.. Journal of Clinical Oncology. 39(15_suppl). 3102–3102. 4 indexed citations
7.
Hamilton, Erika, Ramez N. Eskander, Floor Backes, et al.. (2021). LIO-1: Lucitanib + nivolumab in patients with advanced solid tumors—Updated phase 1b results and initial experience in phase 2 ovarian cancer cohort.. Journal of Clinical Oncology. 39(15_suppl). 5538–5538. 1 indexed citations
8.
Hamilton, Erika, Manish R. Patel, Kenton Wride, et al.. (2020). 556P Initial clinical experience of lucitanib + nivolumab in advanced metastatic solid tumours: Data from the phase Ib/II LIO-1 study (CO-3810-101; NCT04042116). Annals of Oncology. 31. S480–S481. 2 indexed citations
9.
Concin, Nicole, Sandro Pignata, Philipp Harter, et al.. (2020). 885TiP LIO-1: A phase II study of lucitanib + nivolumab in patients (pts) with gynaecological tumours (CO-3810-101; NCT04042116; ENGOT-GYN3/AGO/LIO). Annals of Oncology. 31. S648–S648. 1 indexed citations
10.
Yazıcı, Yusuf, Jeffrey R. Curtis, Akgun Ince, et al.. (2013). Early effects of tocilizumab in the treatment of moderate to severe active rheumatoid arthritis: a one-week sub-study of a randomised controlled trial (Rapid Onset and Systemic Efficacy [ROSE] Study).. Clinical and Experimental Rheumatology. 31(3). 358–64. 11 indexed citations
11.
Weinblatt, Michael E., Joel Kremer, John J. Cush, et al.. (2012). Tocilizumab as monotherapy or in combination with nonbiologic disease‐modifying antirheumatic drugs: Twenty‐four–week results of an open‐label, clinical practice study. Arthritis Care & Research. 65(3). 362–371. 51 indexed citations
12.
Lepley, Denise, Jihye Paik, Timothy Hla, & Fernando Ferrer. (2005). The G Protein–Coupled Receptor S1P2 Regulates Rho/Rho Kinase Pathway to Inhibit Tumor Cell Migration. Cancer Research. 65(9). 3788–3795. 147 indexed citations
13.
Lepley, Denise, et al.. (2002). The Human EMAP-like Protein-70 (ELP70) Is a Microtubule Destabilizer That Localizes to the Mitotic Apparatus. Journal of Biological Chemistry. 277(2). 1301–1309. 60 indexed citations
14.
Lepley, Denise, et al.. (1999). Sequence and expression patterns of a human EMAP-related protein-2 (HuEMAP-2). Gene. 237(2). 343–349. 20 indexed citations
15.
Lepley, Denise & Jill C. Pelling. (1997). Induction of p21/WAF1 and G1 cell-cycle arrest by the chemopreventive agent apigenin. Molecular Carcinogenesis. 19(2). 74–82. 140 indexed citations
16.
Lepley, Denise, W.E. Gillanders, Nancy B. Myers, et al.. (1997). BIOCHEMICAL AND FUNCTIONAL CHARACTERIZATION OF SOLUBLE MULTIVALENT MHC Ld/Fc??1 AND Ld/Fc?? CHIMERIC PROTEINS LOADED WITH SPECIFIC PEPTIDES1. Transplantation. 63(5). 765–774. 4 indexed citations
17.
Birt, Diane F., et al.. (1996). Diet intervention for modifying cancer risk.. PubMed. 395. 223–34. 43 indexed citations
18.
Lepley, Denise, Boyong Li, Diane F. Birt, & Jill C. Pelling. (1996). The chemopreventive flavonoid apigenin induces G2/M arrest in keratinocytes. Carcinogenesis. 17(11). 2367–2375. 156 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Fen-Fen Lin Breakdown of academic impact, for papers by Linette Castillo‐Pichardo Breakdown of academic impact, for papers by Yancun Yin Breakdown of academic impact, for papers by Zachary R. Healy Breakdown of academic impact, for papers by Chang-Hyun Yun Breakdown of academic impact, for papers by Hideharu Odai Breakdown of academic impact, for papers by Li‐Xing Feng Breakdown of academic impact, for papers by Hsin‐Jung Wu Breakdown of academic impact, for papers by Junn-Liang Chang
Rankless by CCL
2026